Abstract

Malignant cardiac tumors are rare and challenging entity. Experience in treating these aggressive and lethal tumors is minimal and management protocols are not well defined and have to rely on case reports, and personal experiences. Most effective therapy for primary cardiac malignancy is a complete surgical resection and the role of chemoradiotherapy is still evolving.

Highlights

  • Malignant cardiac tumors are rare and challenging entity

  • Leiomyosarcoma is sarcoma of smooth muscle cells of endocardium with a peak in the 5th decade (10% of all cardiac malignancies).Usually occurs in the left atrial roof as multiple endocavitary mass and the pulmonary infundibulum and artery, where it presents like pulmonary embolism

  • Transesophageal echocardiography (TEE) is superior to Transthoracic echocardiography (TTE) in identifying small tumors (

Read more

Summary

Epidemiology

The reported prevalence of cardiac tumors ranges from 0.17% to 0.28% in various autopsy series [2] [3] [4]. More frequently tumors of the heart occur in children. Simcha and Nadas reported the incidence of cardiac tumors in children as 0.08% and 0.027% respectively. The prevalence of cardiac neoplasms, unlike other malignancies, have shown little change over. Among the primary cardiac tumors, about 10% - 25% are malignant. About 75% - 90% are sarcoma [5]. Angiosarcomas and unclassified sarcomas being the most common. Metastatic involvement of the heart is even more common with prevalence of 2.3% - 18.3%. Melanoma (hematogenous route), breast and lung carcinoma (direct infiltration and lymphatic route) show the incidence of cardiac metastasis [6]

Angiosarcoma
Leiomyosarcoma
Fibrosarcoma
Rhabdomyosarcoma
Liposarcoma
Cardiac Lymphoma
Obstructive Symptoms
Embolism
Metastasis
Echocardiography
Magnetic Resonance
Computed Tomography
Histological Evaluation
Treatment
Simple Tumor Resection
Complex Tumor Resection
Autotransplantation
Artificial Heart
Cardiac Transplantation
Chemotherapy and Radiotherapy
Prognosis
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.